Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, First-in-human Dose-escalation, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-102 in Subjects With Elevated Intraocular Pressure

NCT00523250 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.

NCT NCT00523250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00523250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, First-in-human Dose-escalation, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-102 in Subjects With Elevated Intraocular Pressure
Lead sponsor
Aerie Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
March 31, 2008
Enrollment
82 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma